Target Information

Target General Infomation
Target ID
T45993
Former ID
TTDS00163
Target Name
Calcium channel
Target Type
Successful
Disease Angina pectoris [ICD9: 413; ICD10: I20]
Allergy [ICD9: 995.3; ICD10: T78.4]
Alzheimer disease [ICD9: 331; ICD10: G30]
Arrhythmia [ICD9: 427; ICD10: I47-I49]
Bipolar disorder [ICD9: 296.0, 296.1, 296.4, 296.5, 296.6, 296.7, 296.8, 300; ICD10: F31, F40-F42]
Cognitive disorders [ICD9: 290-294, 294.0, 780.09, 780.9, 780.93; ICD10: F01-F07, F04, F05, R41.3]
Cardiovascular disorder [ICD10: I00-I99]
Cerebrovascular ischaemia [ICD9: 434.91; ICD10: I61-I63]
Colorectal cancer [ICD9: 153, 154; ICD10: C18-C21]
Cardiac arrhythmias [ICD9: 427; ICD10: I47-I49]
Chronic stable angina [ICD9: 413; ICD10: I20]
Cerebral vasospasm [ICD9: 443.9; ICD10: I73.9]
Epilepsy [ICD10: G40]
Glaucoma [ICD9: 365; ICD10: H40-H42]
Heart failure [ICD9: 428; ICD10: I50]
Heart arrhythmia [ICD10: I47-I49]
High blood pressure; Angina [ICD9: 401, 413; ICD10: I10, I11, I12, I13, I15, I20]
Hyperinsulinemia [ICD10: E16.1]
Hypertension [ICD9: 401; ICD10: I10-I16]
Irritable bowel syndrome [ICD9: 564.1, 787.91; ICD10: A09, K58, K59.1]
Nerve injury [ICD10: T14.4]
Pain [ICD9: 338, 356.0, 356.8,780; ICD10: G64, G90.0, R52, G89]
Psoriasis [ICD9: 696; ICD10: L40]
Unspecified [ICD code not available]
BioChemical Class
Voltage-gated ion channel
Target Validation
T45993
Drugs and Mode of Action
Drug(s) Bepridil Drug Info Approved Chronic stable angina [1], [2]
Clevidipine butyrate Drug Info Approved Hypertension [3], [4]
Felodipine Drug Info Approved Hypertension [5], [6]
Isradipine Drug Info Approved Hypertension [7], [8]
Nicardipine Drug Info Approved High blood pressure; Angina [9], [10]
Nimodipine Drug Info Approved Cerebral vasospasm [11], [12]
Nisoldipine Drug Info Approved Hypertension [13], [14]
DIPROTEVERINE HYDROCHLORIDE Drug Info Phase 3 Angina pectoris [15]
Arverapamil Drug Info Phase 2 Irritable bowel syndrome [16]
HBI-3000 Drug Info Phase 2 Heart arrhythmia [17]
Nexopamil Drug Info Phase 2 Hypertension [18]
S-2150 Drug Info Phase 2 Angina pectoris [19]
CM2489 Drug Info Phase 1 Psoriasis [20]
Elpetrigine Drug Info Phase 1 Bipolar disorder [21]
YM-16151-4 Drug Info Phase 1 Hypertension [22]
Rycals Drug Info Preclinical Heart failure [23]
AE-0047 Drug Info Discontinued in Preregistration Hypertension [24]
Monatepil maleate Drug Info Discontinued in Preregistration Angina pectoris [25]
Palonidipine hydrochloride Drug Info Discontinued in Preregistration Hypertension [26]
Semotiadil Drug Info Discontinued in Preregistration Hypertension [27]
Anipamil Drug Info Discontinued in Phase 3 Hypertension [28]
ELGODIPINE HYDROCHLORIDE Drug Info Discontinued in Phase 3 Angina pectoris [29]
S-12968 Drug Info Discontinued in Phase 3 Hypertension [30]
Tetrandrine Drug Info Discontinued in Phase 3 Colorectal cancer [31]
AM336 Drug Info Discontinued in Phase 2 Pain [32]
BRL-32872A Drug Info Discontinued in Phase 2 Cardiac arrhythmias [33]
CD-349 Drug Info Discontinued in Phase 2 Hypertension [34]
Dopropidil Drug Info Discontinued in Phase 2 Angina pectoris [35]
FLOSATIDIL Drug Info Discontinued in Phase 2 Angina pectoris [36]
Levosemotiadil Drug Info Discontinued in Phase 2 Cardiac arrhythmias [37]
LIFARIZINE HYDROCHLORIDE Drug Info Discontinued in Phase 2 Nerve injury [38]
S-312-d Drug Info Discontinued in Phase 2 Epilepsy [39]
TAMOLARIZINE HYDROCHLORIDE Drug Info Discontinued in Phase 2 Cognitive disorders [40]
CEREBROCRAST Drug Info Discontinued in Phase 1 Nerve injury [41]
CERM-11956 Drug Info Discontinued in Phase 1 Angina pectoris [42]
IGANIDIPINE HYDROCHLORIDE Drug Info Discontinued in Phase 1 Glaucoma [43]
KT-362 Drug Info Discontinued in Phase 1 Heart arrhythmia [44]
NP-252 Drug Info Discontinued in Phase 1 Hypertension [45]
SM-6586 Drug Info Discontinued in Phase 1 Hypertension [46]
SR-33805 Drug Info Discontinued in Phase 1 Angina pectoris [47]
AHR-16303B Drug Info Terminated Hypertension [48]
AHR-16462B Drug Info Terminated Hypertension [49]
AJ-3941 Drug Info Terminated Cerebrovascular ischaemia [50]
CD-832 Drug Info Terminated Angina pectoris [51]
Clentiazem Drug Info Terminated Angina pectoris [52]
Darodipine Drug Info Terminated Cerebrovascular ischaemia [53]
DHP-218 Drug Info Terminated Hypertension [54]
E-2050 Drug Info Terminated Cerebrovascular ischaemia [55]
Emopamil Drug Info Terminated Cerebrovascular ischaemia [56]
LAS-30538 Drug Info Terminated Hyperinsulinemia [57]
NALTIAZEM HYDROCHLORIDE Drug Info Terminated Angina pectoris [58]
NNC-09-0026 Drug Info Terminated Cerebrovascular ischaemia [59]
NS-638 Drug Info Terminated Cerebrovascular ischaemia [60]
NS-649 Drug Info Terminated Alzheimer disease [61]
NS-696 Drug Info Terminated Epilepsy [62]
Pranidipine Drug Info Terminated Angina pectoris [63]
RS-93522 Drug Info Terminated Hypertension [64]
RWJ-22108 Drug Info Terminated Allergy [65]
RWJ-37868 Drug Info Terminated Epilepsy [66]
SB-206284A Drug Info Terminated Cerebrovascular ischaemia [67]
SB-237376 Drug Info Terminated Arrhythmia [68]
SDZ-249482 Drug Info Terminated Pain [69]
SIM-6080 Drug Info Terminated Angina pectoris [70]
Siratiazem Drug Info Terminated Angina pectoris [71]
SKF-96365 Drug Info Terminated Angina pectoris [72], [73]
SQ-33351 Drug Info Terminated Hypertension [74]
UK-51656 Drug Info Terminated Cardiovascular disorder [75]
VUF-8929 Drug Info Terminated Heart failure [76]
Z-6568 Drug Info Terminated Hypertension [77]
ZM-224832 Drug Info Terminated Hypertension [78]
Modulator AE-0047 Drug Info [79]
AGN-190744 Drug Info
AHR-16303B Drug Info [48]
AHR-16462B Drug Info [80]
AJ-3941 Drug Info [81]
AM336 Drug Info
Anipamil Drug Info [82]
Arverapamil Drug Info
BELFOSDIL Drug Info
Bepridil Drug Info [83]
BRL-32872A Drug Info
CD-349 Drug Info [84]
CD-832 Drug Info [85]
CD-832.HCL Drug Info
Clentiazem Drug Info
Clevidipine butyrate Drug Info [3], [4]
CM2489 Drug Info
Darodipine Drug Info [86]
DHP-218 Drug Info [87]
Dopropidil Drug Info [88]
E-2050 Drug Info
Emopamil Drug Info [56]
Isradipine Drug Info [83]
KT-362 Drug Info [89]
LAS-30538 Drug Info [57]
leualacin Drug Info
Levosemotiadil Drug Info [90]
Monatepil maleate Drug Info [91]
NNC-09-0026 Drug Info [92]
NS-638 Drug Info [93]
NS-649 Drug Info [94]
NS-696 Drug Info [95]
Palonidipine hydrochloride Drug Info [96]
Pranidipine Drug Info [97]
RWJ-22108 Drug Info [98]
RWJ-37868 Drug Info [99]
Rycals Drug Info [100]
S-2150 Drug Info [19]
SB-206284A Drug Info [101]
SB-237376 Drug Info [68]
SDZ-249482 Drug Info [102]
Siratiazem Drug Info [103]
SKF-96365 Drug Info [104]
SQ-33351 Drug Info [105]
SR-33805 Drug Info [106]
SR-33805A Drug Info [107], [108]
UK-51656 Drug Info [109]
VUF-8929 Drug Info [110]
YM-16151-4 Drug Info [22]
Z-6568 Drug Info [111]
ZM-224832 Drug Info [112]
Inhibitor CEREBROCRAST Drug Info [113], [108]
Antagonist CERM-11956 Drug Info [114], [108]
DIPROTEVERINE HYDROCHLORIDE Drug Info [115], [108]
FLOSATIDIL Drug Info [108]
SM-6586 Drug Info [116]
Tetrandrine Drug Info [117]
Agonist ELGODIPINE HYDROCHLORIDE Drug Info [118], [108]
Blocker Elpetrigine Drug Info [119]
Felodipine Drug Info [120]
HBI-3000 Drug Info [121]
IGANIDIPINE HYDROCHLORIDE Drug Info [122], [108]
LIFARIZINE HYDROCHLORIDE Drug Info [123], [108]
NALTIAZEM HYDROCHLORIDE Drug Info [124], [108]
Nexopamil Drug Info [18]
Nicardipine Drug Info [125]
Nimodipine Drug Info [126]
Nisoldipine Drug Info [127]
NP-252 Drug Info [128], [108]
RS-93522 Drug Info [129], [108]
S-12968 Drug Info [130]
S-312-d Drug Info [131]
Semotiadil Drug Info [132]
SIM-6080 Drug Info [133], [108]
TAMOLARIZINE HYDROCHLORIDE Drug Info [134], [108]
TELUDIPINE HYDROCHLORIDE Drug Info [135], [108]
References
REF 1New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
REF 2(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2337).
REF 32008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
REF 4Clevidipine: a short-acting intravenous dihydropyridine calcium channel blocker for the management of hypertension. Pharmacotherapy. 2010 May;30(5):515-28.
REF 5(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4190).
REF 6FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 075896.
REF 7(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4488).
REF 8FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 077169.
REF 9FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022276.
REF 10(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2559).
REF 11Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs. 2009 Mar;14(1):67-84.
REF 12(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2523).
REF 13FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 079051.
REF 14(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2524).
REF 15Diproteverine (BRL 40015): a new type of calcium antagonist with potential antianginal properties. Eur J Pharmacol. 1991 Jan 17;192(3):317-27.
REF 16Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
REF 17ClinicalTrials.gov (NCT01235156) Efficacy and Safety of Sulcardine Sulfate Tablets in Patients With Premature Ventricular Contractions. U.S. National Institutes of Health.
REF 18Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94.
REF 19Pharmacodynamics of S-2150, a simultaneous calcium-blocking and alpha1-inhibiting antihypertensive drug, in rats. J Pharm Pharmacol. 2000 Mar;52(3):273-80.
REF 20Clinical pipeline report, company report or official report of CalciMedica (2011).
REF 21Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027454)
REF 22Antianginal effects of YM-16151-4 in various experimental angina models. J Cardiovasc Pharmacol. 1993 May;21(5):701-8.
REF 23Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030217)
REF 24Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001931)
REF 25Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001558)
REF 26Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001157)
REF 27Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000198)
REF 28Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000258)
REF 29Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000324)
REF 30Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000221)
REF 31Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022136)
REF 32Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013107)
REF 33Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000403)
REF 34Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000220)
REF 35Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000432)
REF 36Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005965)
REF 37Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005516)
REF 38Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003892)
REF 39Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002235)
REF 40Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000299)
REF 41Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006562)
REF 42Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000166)
REF 43Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000292)
REF 44Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000337)
REF 45Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000291)
REF 46Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002576)
REF 47Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002436)
REF 48AHR-16303B, a novel antagonist of 5-HT2 receptors and voltage-sensitive calcium channels. J Cardiovasc Pharmacol. 1991 Jan;17(1):41-53.
REF 49Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000297)
REF 50Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002238)
REF 51Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001566)
REF 52Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000188)
REF 53Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000417)
REF 54Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000422)
REF 55Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016308)
REF 56Calcium entry and 5-HT2 receptor blockade in oliguric ischaemic acute renal failure: effects of levemopamil in conscious rats. Br J Pharmacol. 1996 Mar;117(6):1348-54.
REF 57The calcium channel blocker LAS 30538, unlike nifedipine, verapamil, diltiazem or flunarizine, potently inhibits insulin secretion in-vivo in rats and dogs. J Pharm Pharmacol. 1992 Oct;44(10):851-5.
REF 58Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000300)
REF 59Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003940)
REF 60Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005354)
REF 61Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005353)
REF 62Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005355)
REF 63Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000287)
REF 64Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002793)
REF 65Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002359)
REF 66Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008896)
REF 67Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007384)
REF 68Electrophysiologic effects of SB-237376: a new antiarrhythmic compound with dual potassium and calcium channel blocking action. J Cardiovasc Pharmacol. 2003 Mar;41(3):414-21.
REF 69Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010408)
REF 70Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000149)
REF 71Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001949)
REF 72(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2441).
REF 73Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000362)
REF 74Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002577)
REF 75Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003366)
REF 76Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009533)
REF 77Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007046)
REF 78Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002886)
REF 79AE0047-mediated calcium channel blocking in vascular smooth muscles. Gen Pharmacol. 1997 Sep;29(3):337-43.
REF 80A pharmacological and biochemical examination of AHR-16462B, a novel calcium antagonist coronary vasodilator/antihypertensive. Drug Development Research. 01/1991; 22(3):259-271.
REF 81Prevention by the new Ca2+ channel antagonist, AJ-3941, of loss of endothelium-dependent relaxation after subarachnoid hemorrhage in rats. Eur J Pharmacol. 1996 Nov 21;315(3):297-303.
REF 82Effects of the novel calcium channel blocker, anipamil, on the isolated rabbit heart. Comparison with verapamil and gallopamil. Naunyn Schmiedebergs Arch Pharmacol. 1992 Sep;346(3):339-44.
REF 83Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
REF 84A new Ca-antagonist, CD-349, binding to the Ca-channel of rat myocardium and brain and hog coronary artery. Jpn J Pharmacol. 1988 Dec;48(4):453-62.
REF 85Effects of CD-832, a new calcium antagonist, on intracranial pressure in anesthetized dogs. Life Sci. 1998;62(19):PL283-8.
REF 86Effect of cromakalim on contractions in rabbit isolated renal artery in the presence and absence of extracellular Ca2+. Br J Pharmacol. 1989 Dec;98(4):1303-11.
REF 87Effect of DHP-218, a novel dihydropyridine phosphonate, on atrioventricular nodal conductivity compared with its vascular effect in dogs. J Cardiovasc Pharmacol. 1987 Sep;10(3):274-9.
REF 88Effects of bepridil and CERM 4205 (ORG 30701) on the relation between cardiac cycle length and QT duration in healthy volunteers. Am J Cardiol. 1990 Sep 1;66(5):636-41.
REF 89Comparative cardiac effects of KT-362 and verapamil in isolated heart--correlation to calcium channel current depression. J Cardiovasc Pharmacol. 1991 Oct;18(4):594-604.
REF 90Binding study of semotiadil and levosemotiadil with alpha(1)-acid glycoprotein using high-performance frontal analysis. Anal Biochem. 1999 Oct 1;274(1):27-33.
REF 91Antihypertensive, antiatherosclerotic, and plasma lipid-lowering effects of monatepil, a novel calcium antagonist with alpha 1-adrenoceptor-blocking activity in experimental animals. Am J Hypertens. 1994 Oct;7(10 Pt 2):131S-40S.
REF 92Pharmacological profile of a novel neuronal calcium channel blocker includes reduced cerebral damage and neurological deficits in rat focal ischemia. Pharmacol Biochem Behav. 1994 May;48(1):77-85.
REF 93Pharmacological profile and anti-ischemic properties of the Ca(2+)-channel blocker NS-638. Neurol Res. 1995 Oct;17(5):353-60.
REF 94Effects of Ca2+ and Na+ channel inhibitors in vitro and in global cerebral ischaemia in vivo. Eur J Pharmacol. 1997 Aug 6;332(2):121-31.
REF 95Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005355)
REF 96Effect of palonidipine hydrochloride (TC-81), a novel calcium antagonist, on the canine coronary artery. Nihon Yakurigaku Zasshi. 1993 Jul;102(1):23-33.
REF 97Pranidipine, a new 1,4-dihydropyridine calcium channel blocker, enhances cyclic GMP-independent nitric oxide-induced relaxation of the rat aorta. Mol Cell Biochem. 1998 Jan;178(1-2):335-43.
REF 98Design and discovery of RWJ 22108--a novel bronchoselective calcium channel blocker. Drug Des Discov. 1998 May;15(3):135-48.
REF 99Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008896)
REF 100Fixing ryanodine receptor Ca2+ leak - a novel therapeutic strategy for contractile failure in heart and skeletal muscle. Drug Discov Today Dis Mech. 2010 SUMMER; 7(2): e151-e157.
REF 101The effects of SB 206284A, a novel neuronal calcium-channel antagonist, in models of cerebral ischemia. J Cereb Blood Flow Metab. 1997 Apr;17(4):421-9.
REF 102Physiology and Pharmacology of the Vanilloid Receptor. Curr Neuropharmacol. 2006 January; 4(1): 1-15.
REF 103Comparison of the effects of diltiazem and its analogue siratiazem on contractility in arteries, ileum and cardiac muscle. J Auton Pharmacol. 1995 Apr;15(2):107-13.
REF 104The transient receptor potential channel antagonist SKF96365 is a potent blocker of low-voltage-activated T-type calcium channels. Br J Pharmacol. 2010 Jul;160(6):1464-75.
REF 105Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002577)
REF 106Effects of a new class of calcium antagonists, SR33557 (fantofarone) and SR33805, on neuronal voltage-activated Ca++ channels. J Pharmacol Exp Ther. 1994 Dec;271(3):1348-52.
REF 107Vascular calcium overload produced by vitamin D3, in rats. Effect of treatment with SR 33805, a novel calcium entry blocker. Cardiovasc Res. 1995 Dec;30(6):1038-43.
REF 108Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
REF 109Long-acting dihydropyridine calcium antagonists. 4. Synthesis and structure-activity relationships for a series of basic and nonbasic derivatives of 2-[(2-aminoethoxy)methyl]-1,4-dihydropyridine calcium antagonists. J Med Chem. 1990 Feb;33(2):585-91.
REF 110In vitro and in vivo characterization of a calcium modulator of the diphenylalkylamine type with selective coronary dilatory properties. Arzneimittelforschung. 1997 Nov;47(11):1211-8.
REF 111Determination of the dihydropyridine aryloxypropanolamine Z6568 and its acidic metabolites in plasma, urine and tissues by solid phase extraction and liquid chromatography/negative-ion mass spectrometry. J Mass Spectrom. 1996 Sep;31(9):994-1002.
REF 112Diuretic and antihypertensive activity of ZENECA ZM224,832: a novel eukalemic diuretic with calcium channel blocking activity. Pharmacology. 1994 Mar;48(3):167-75.
REF 113The dihydropyridine analogue cerebrocrast blocks both T-type and L-type calcium currents. Can J Physiol Pharmacol. 2009 Nov;87(11):923-32.
REF 114The anti-ischaemic activity of the novel compound, CERM 11956, compared with that of bepridil and nifedipine in isolated guinea-pig hearts. Eur J Pharmacol. 1988 May 10;149(3):195-203.
REF 115Prenatal toxicity studies in rats and rabbits with the calcium channel blocker diproteverine. Reprod Toxicol. 1996 Jan-Feb;10(1):43-9.
REF 116Calcium channel blocking properties of SM-6586 in rat heart and brain as assessed by radioligand binding assay. Jpn J Pharmacol. 1993 Oct;63(2):165-9.
REF 117Tetrandrine: a novel calcium channel antagonist inhibits type I calcium channels in neuroblastoma cells. Neuropharmacology. 1991 Dec;30(12A):1325-31.
REF 118The calcium channel blocker amlodipine exerts its anti-proliferative action via p21(Waf1/Cip1) gene activation. FASEB J. 2004 Oct;18(13):1516-23.
REF 119Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
REF 120Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. Epub 2008 Oct 30.
REF 121Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. J Cardiovasc Pharmacol. 2011 Jan;57(1):79-85.
REF 122Improving effects of topical administration of iganidipine, a new calcium channel blocker, on the impaired visual evoked potential after endothelin-1 injection into the vitreous body of rabbits. CurrEye Res. 2000 Feb;20(2):101-8.
REF 123The effect of lifarizine (RS-87476), a novel sodium and calcium channel modulator, on ischaemic dopamine depletion in the corpus striatum of the gerbil. Br J Pharmacol. 1993 May;109(1):175-7.
REF 124Assessment of hyperglycemia after calcium channel blocker overdoses involving diltiazem or verapamil. Crit Care Med. 2007 Sep;35(9):2071-5.
REF 125Effect of intracoronary nicardipine on cardiac enzymes after elective percutaneous coronary intervention. Clin Cardiol. 2009 Jun;32(6):315-20.
REF 126Influence of bupropion and calcium channel antagonists on the nicotine-induced memory-related response of mice in the elevated plus maze. Pharmacol Rep. 2009 Mar-Apr;61(2):236-44.
REF 127RT-PCR and pharmacological analysis of L-and T-type calcium channels in rat carotid body. Adv Exp Med Biol. 2009;648:105-12.
REF 128Pharmacological characteristics of NP-252, a new dihydropyridine slow Ca2+ channel blocker, in isolated rabbit vascular smooth muscle and guinea pig myocardium: vascular selectivity. Eur J Pharmacol.1991 Oct 22;203(3):337-44.
REF 129Intranasal delivery of RS-93522, a dihydropyridine-type calcium-channel antagonist. Pharm Res. 1991 Jan;8(1):134-5.
REF 130(+)-S-12967 and (-)-S-12968: 1,4-dihydropyridine stereoisomers with calcium channel agonistic and antagonistic properties in rat resistance arteries. Br J Pharmacol. 1991 Jul;103(3):1703-8.
REF 131Protective effects of a selective L-type voltage-sensitive calcium channel blocker, S-312-d, on neuronal cell death. Biochem Pharmacol. 2004 Mar 15;67(6):1153-65.
REF 132Thyroid hypertrophic effect of semotiadil fumarate, a new calcium antagonist, in rats. J Toxicol Sci. 2000 May;25(2):121-30.
REF 133Determination of the calcium antagonist SIM6080 and its N- and O-demethylated metabolites in plasma, urine and tissues by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1996 Feb 9;676(1):77-85.
REF 134Reversal of multidrug resistance in human leukemia K562 by tamolarizine, a novel calcium antagonist. Jpn J Pharmacol. 2000 Mar;82(3):265-8.
REF 135Effects of R-enantiomer (GR66234A) and L-enantiomer (GR66235A) of telupidine, a new dihydropyridine derivative, on cell lines displaying the multidrug resistant phenotype. Haematologica. 1994 Jul-Aug;79(4):328-33.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.